CRISPR | Cas9 Tools ? Global Market and Patent Landscape Report till 2025

Posted by Divya Rathi on March 6th, 2019

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) is an innovative genome editing tool that has recently transformed the arena of human genetic engineering. CRISPR/Cas9 can modulate gene expression in plants, humans, and animals based on an RNA-guided mechanism. The CRISPR/Cas9 programmable nucleases are the preferred choices over traditional genome editing technologies, which is attributable to ease in target design, the facility to target multiple sites in one step, and predictable off-target sites. The global markets for CRISPR-Cas9 genome editing were estimated at .22 billion in 2017. It is expected to reach .3 billion by 2025 growing at a CAGR of 20.19 per cent.


The technique is being effectively employed in therapeutics development, and research and design tools. Large biotech companies like Millipore Sigma (earlier Sigma Aldrich), Thermo Fisher Scientific, Toolgen, Genecopeia, Horizon Discovery, and Agilent Technologies and pharmaceuticals like Novartis, Vertex, Bayer AG, AstraZeneca, Evolva, Juno Therapeutics, and GE Healthcare have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes. They are forming strategic alliances with crucial CRISPR technology companies like Crispr Therapeutics, Editas Medicine, Caribou Biosciences and Intellia Therapeutics to devise gene-based therapies for various genetic diseases.

As the research and development investment in the technology is growing by leaps and bounds, the technology’s potential has been explored in newer areas of animal and disease model development, drug compound and target screening, and agriculture and nutritional health products. The ambidexterity of the CRISPR/Cas9 system in locating and altering specific genes is assisting researchers and scientists in understanding diseases using cells and animal models. Cas9 system has helped in achieving significant advancements in drug discovery and precluding genetic as well as cardiovascular diseases in humans. Novel treatments for single-gene disorders such as cystic fibrosis, haemophilia and sickle cell disease are being researched using Cas9 tools. This technique is anticipated to be useful in the prevention and cure of complex conditions, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection.

In 2017, the global CRISPR-Cas9 mediated drug discovery and development market are expected to jump to ,305 million by 2020 and further grow by a CAGR of 23.8 per cent over a period of eight years from 2017 to 2025. The technology has the potential to develop genuinely personalized treatments and therapeutic medicines. The Clinical therapy market is expected to contribute significantly to the overall CRISPR-Cas9 tools market by 2025.

CRISPR-Cas9 tools will play a multifarious role in agriculture by enabling the industry in editing crops to make them more nutritious, enhanced taste, disease resistant, and less susceptible to drought. Agriculture and plant breeding application segment is restricted in growth by several potential regulatory requirements and ethical apprehensions. Established agritechs like DowDuPont, Monsanto, Syngenta, and new entrants like Pairwise are also extensively active in the CRISPR landscape. Industrial biotechnology and animal biotechnology together will contribute modestly to the global CRISPR-Cas9 genome editing market

Product type-based market segments include editing tools, cell lines, animal models, and plant breeding products. Regional-based market segments include North America, Europe, APAC and the Rest of World (RoW). The North American market has the maximum number of companies dealing with CRISPR-Cas9 products or services. The Chinese government is heavily committed to CRISPR research and has awarded more than 23 million yuan (.5 million) to 42 CRISPR projects.

CRISPR-Cas9 patent landscape is dominated by universities and research institutes over commercial companies. Out of the top 15 patent owners in the CRISPR-Cas9 patent space, companies represent approximately 40 per cent while five universities and four research institutes rank among the top 15 owners. US and Chinese academic institutions are actively pursuing research activities in CRISPR domain.


To know more about detailed TOC visit -


Like it? Share it!

Divya Rathi

About the Author

Divya Rathi
Joined: February 22nd, 2019
Articles Posted: 11

More by this author